The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Bronchospasm - Wheezing - Asthma
Publications
Ehrmann S, Barbier F, Demiselle J, Quenot JP, Herbrecht JE, Roux D, Lacherade JC, Landais M, Seguin P, Schnell D, Veinstein A, Gouin P, Lasocki S, Lu Q, Beduneau G, Ferrandiere M, Plantefève G, Dahyot-Fizelier C, Chebib N, Mercier E, Heuzé-Vourc'h N, Resp
Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia.
The New England journal of medicine 2023 Oct 25;; — 2023 Oct 25
Amikacin Liposome Inhalation Suspension for Complex Lung Disease.
The Senior care pharmacist 2020 Apr 01;35;162-170 — 2020 Apr 01 — 162-170
Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review.
The European respiratory journal 2014 Aug;44;382-93 — 2014 Aug — 382-93
Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with gram-negative pneumonia and acute renal failure.
Journal of aerosol medicine and pulmonary drug delivery 2011 Aug;24;183-90 — 2011 Aug — 183-90